The European Society for Medical Oncology (ESMO) posted on LinkedIn:
“Intercepting pre-malignant lesions before significant immune dysregulation is a novel area of Translational Research. Two presentations at MAP 2025 provide evidence to support this new approach.
In one study in Lung Cancer, reactive T cell receptors (TCRs) with an exhausted phenotype were detected in the blood years before invasive disease.
Another study found that pre-cancer T-cell landscapes were characterised by more regulatory and exhausted T cells than healthy samples, suggesting a distinct microenvironment that could be targeted for immune interception.
Read the full commentary in the ESMO Daily Reporter.”
More from European Society for Medical Oncology on OncoDaily.